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IMMUNOSUPPRESSION AND THE 
BIDIRECTIONAL PARADIGM OF 
TRANSPLANTATION IMMUNOLOGY 
Thomas E. Starz.l and Anthony J. Demetris 
A cquired transplantation tolerance without immunosuppression was described 
l\.by Billingham, Brent and Medawar J·2 more than four decades ago follow-
ing the injection of immune competent adult spleen cells into immunologi-
cally immature mice in utero or perinatally. The engrafted donor cells flour-
ished, perpetuated themselves and were thought in effect to have endowed the 
recipient with the donor immune system. This explanation of tolerance by 
immunologic replacement was strengthened by Main and Prehn3.4 who dem-
onstrated the same outcome in irradiated adult mice, whose cytoablated 
hematolymphopoietic cells were reconstituted with donor bone marrow. 
The anticipated clinical application of tolerance induction for transplanta-
tion was temporarily derailed in 1957 when Billingham and Brent showed in 
mice5•6 and Simonsen in chickens7 that graft-versus-host ("runt") disease (GVHD) 
was a danger in these immunologically "unbalanced" systems in rough pro-
portion to the degree of MHC disparity. In spite of the same limitations as 
with the radiation chimera models, a strategy for clinical bone marrow trans-
plantation could be assembled directly from the Main-Prehn experiments, with 
similar results. Stable drug free chimerism could be induced in irradiated ani-
mals using MHC matched donor marrow, but otherwise there was an intoler-
able incidence of GVHD. 
Translation of these experiments into successful clinical bone marrow trans-
plantation in 19688•9 was supremely gratifying because it had been so logical 
as Nobel Laureate Thomas has summarized. 1o However, the achievement ef-
fectively detached from a scientific base, surgeons who by this time had re-
corded thousands of successful whole organ transplantations under continuous 
immunosuppression-without host preconditioning, dependence on MHC match-
ing or problems with GVHD. The avalanche of whole organ cases had begun 
in 1962 when azathioprine was combined with prednisone. I J A characteristic 
cycle was identified in which rejection could be reversed surprisingly easily 
with prednisone. More importantly, the need later on for maintenance immu-
nosuppression frequently declined. The same sequence has been seen since 
with all other organs transplanted and with all of the immunosuppressive regi-
mens. Something had changed in the host, the graft or both. But what? 
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Thirty years and a revolution in immunology later, 
the question was answered. 12-17 Donor leukocytes of 
bone marrow origin which are part of the structure 
of all complex grafts (multilineage "passenger leuko-
cytes"18.19) had migrated from the organs and survived 
ubiquitously in the recipients. Thus, organ transplan-
tation and acceptance was a cryptic example of cell 
transplantation whereby a small fragment of extra-
medullary donor bone marrow had migrated and 
become assimilated into the overwhelmingly larger 
immunologic network of the host (micro chimerism) 
(Fig. 29.1.1). The cell movement was in both direc-
tions, the interstitial leukocyte constituency of the 
grafts becoming predominantly that of the recipient. 
In successful cases, graft and host were both genetic 
composites!!! 
From this information, we proposed a two-way 
paradigm of transplantation immunology.12-17 It holds 
chat the immunologic reaction following whole or-
gan transplantation is bidirectional (GVH as well as 
HVG) and mutually canceling, providing the two 
participants in the David/Goliath mismatch survive 
the initial confrontation. In clinical practice, this re-
quires an umbrella of immunosuppression that cov-
ers both equally. Although the chimeric leukocytes 
are multilineage,20.21 the dendritic cells of Steinman 
and Cohen22.23 are thought to be key participants.12-19.24 
With the two-way paradigm, virtually every pre-
viously enigmatic problem observation after whole 
organ transplantation can be explained: why organ 
grafts can be tolerogenic, why GVHD does not de-
velop after the transplantation of immunologically 
active grafts such as the liver and intestine,25 and why 
HLA. matching is so poorly predictive of outcome.26 
It also has called into question the deeply ingrained 
assumption that tolerance induction for whole organ 
recipients requires host preconditioning in prepara-
tion for a variety of donor leukocyte preparations. 
Instead, the development of donor specific non-
reactivity is the consequence of the reciprocal im-
munologic transaction that is merely chaperoned, not 
caused, by diverse techniques of immunosuppression 
with which this book is concerned. Thus, the vari-
ous drugs which interrupt various stages of the im-
mune reaction are merely permissive of a natural event 
chat is ultimately the same with all successful agents, 
no matter what their site of action. 
If this hypothesis were valid, it should be pos-
sible to augment the natural passenger leukocyte traffic 
in organ recipients. Historical efforts (of which 
Fig. 29. 1. 1. Mechanism of 
whole organ graft accep-
tance involving a graft-ver-
sus-host (CVH) reaction by 
the bone marrow-derived 
donor leukocytes in the 
graft that are pitted against 
the whole recipient immu-
nologic apparatus ([HVCJ 
host-versus-graft, rejec-
tion). In standard clinical 
practice, the recipient is 
not preconditioned. 
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Monaco's were most noteworthy27) to give extra do-
nor antigen in the form of bone marrow27-32 or do-
nor blood transfusions33-36 were hampered in design 
or execution by the assumption that the infused cells 
would have a transient survival without precondition-
ing, justifiable anxiety about GVHD with any form 
of preconditioning and a lack of information about 
the appropriate timing of leukocyte infusions. Such 
trials have either failed outright or yielded equivocal 
results. Whether the administered donor leukocytes 
survived in these trials was unknown because no one 
looked for chimerism postoperatively. 
The information that chimerism regularly follows 
successful whole organ transplantation exposed a 
perioperative window of opportunity during which 
unaltered MHC incompatible bone marrow or leu-
kocyte donor specific blood could be given safely 
without recipient preparation or deviation from the 
standard clinical practices of immunosuppression that 
had empirically evolved.37 In Pittsburgh, leukocyte 
augmentation (3 x 108/kg unaltered donor bone mar-
row perioperatively) has been carried out in 50 non-
preconditioned recipients of cadaveric kidneys, liv-
ers, hearts and lungs of whom only the first 18 have 
been recently reported; however, all 50 are well. 
Chimerism estimated to be > 1 000 times greater than 
that occurring spontaneously could be reliably pro-
duced and sustained under standard FK506-prednisone. 
Their persistent blood chimerism (usually> 1 %) trend 
toward donor specific nonreactivity and universal sur-
vival (along with the next 32 recipients) have marked 
them as an advantaged cohort37 despite the fact that 
early (and easily controlled) rejection has been docu-
mented in more than half of the cases. Serious GVHD 
has not been observed. We have cautioned that chi-
merism is not synonymous with tolerance, but only 
a necessary condition for its attainment. The pace of 
drug weaning with the ultimate objective of drug dis-
continuance will have to be determined in each of 
these patients individually. 
The bidirectional paradigm closes the vast gap 
between the bone marrow and organ transplant fields 
by showing how their perceived differences are di-
rect reflections of treatment strategy-leaving intact 
the mutually censoring immunologic limbs in the 
whole organ recipient and deliberately trying ra re-
move one of these in the conventional bone marrow 
recipient. However, in both kinds of patient, the 
appearance of MHC restricted vera and suppressor 
cells, enhancing antibodies and changes in cyrakine 
profiles can be construed as by-products of and ac-
cessory ra the seminal event of mixed chimerism. In 
the bone marrow recipient, the trace population is 
of host cells despite drastic cyraablationJ8 . 1'J and in 
the whole organ recipient the trace leukocyte popu-
lation is of donor cells. 
The fusion of whole organ and bone marrow trans-
plantation into a unitarian world invites questions 
about the meaning of acquired transplantation toler-
ance. It seems obvious that essentially all examples 
of transplantation tolerance observed in either hu-
man whole organ or bone marrow recipients are in-
dependent of any single recipient organ or region and 
are thus "peripheral" rather than control. This in-
sight about what is actually accomplished with the 
successful transplantation of either whole organs or 
bone marrow will require re-examination at many te-
nets of "classical" transplantation immunology, and 
should lead to improvements in therapy. 
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